Klin Padiatr 2018; 230(06): 342-343
DOI: 10.1055/s-0038-1675282
Abstracts
Georg Thieme Verlag KG Stuttgart · New York

BH-3 mimetics combined with CUSP9 – Multi-targeting meets repurposing

Authors

  • ME Halatsch

    1   Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany

  • RE Kast

    2   IIAIGC Study Center, Burlington, VT, U.S.A.

  • A Westhoff

    3   Department of Pediatric and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany

  • A Dwucet

    1   Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany

  • M Hlavac

    1   Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany

  • MD Siegelin

    4   Department of Pathology, Columbia University Medical Center, New York, NY, U.S.A.

  • CR Wirtz

    1   Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany

  • G Karpel-Massler

    1   Department of Neurosurgery, Ulm University Medical Center, Ulm, Germany
Further Information

Publication History

Publication Date:
06 November 2018 (online)

Also available at
 

Objective:

Repurposing represents a promising approach to safely accelerate the clinical application of therapeutics with anti-cancer activity. In this study, we examined whether inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL, by the BH-3 mimetic ABT263, enhances the biological effects of the repurposed CUSP9 regimen in an in vitro setting of glioblastoma.

Methods:

We applied MTT assays to assess cellular proliferation. Annexin V/PI and TMRE staining were used to examine apoptosis. Western blotting, RT-PCR and specific knockdown experiments using siRNA were employed to examine molecular mechanisms of action.

Results:

Bcl-2/Bcl-xL inhibition yielded synergistic anti-proliferative effects across a wide panel of established and primary cultured glioblastoma cells when combined with CUSP9 which had been reduced to only one tenth of its original concentration (CUSP9 1/10). The combination treatment also led to enhanced apoptosis with loss of mitochondrial membrane potential and activation of caspases. On the molecular level, CUSP9 1/10 counteracted ABT263-mediated upregulation of Mcl-1 and led to suppression of Bcl-xL. Silencing of Mcl-1 enhanced ABT263-mediated apoptosis, indicating that Mcl-1 is crucial for the induction of cell death conveyed by the combination treatment. Levels of Mcl-1 mRNA were not decreased following combination therapy, and co-treatment with cycloheximide showed reduced protein stability, pointing towards a post-translational mechanism of action.

Conclusion:

These data suggest that Bcl-2/Bcl-xL inhibition enhances the susceptibility of glioblastoma cells towards CUSP9, allowing dramatic dose reduction and potentially decreased toxicity when applied clinically. A clinical trial involving the original CUSP doses (CUSP9v3) is currently ongoing in our institution (NCT02770378). The Bcl-2/Bcl-xL inhibitor ABT263 is in clinical trials and might represent a valuable adjunct to the original CUSP.